This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
|Articles|September 1, 2006
Prepping for the 2006-2007 flu season
Author(s)Judith Asch-Goodkin
Advertisement
The CDC's Advisory Committee on Immunization Practices has issued an updated set of influenza recommendations for the coming influenza season (MMWR "Recommendations and Reports," July 28). Principal changes from last year include:
Speaking of the possibility of a flu vaccine shortage: The Food and Drug Administration has approved four manufacturers' formulation of a flu vaccine for the 2006-2007 flu season. Those four (GlaxoSmithKline, Chiron, MedImmune, and Sanofi Pasteur) report that they expect to produce a total of 100 million doses for the coming season. But, as the FDA said in a statement, that projection could change as manufacturing continues.
Advertisement
Related to this article
XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.
Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.
New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.
CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.
The AAP's 2026-2027 policy recommends universal vaccination for infants 6-23 months and a risk-based single dose for children 2-18 years.
AAP guidance expands RSV immunization eligibility for children aged 8 through 19 months at high risk of severe disease.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
3
FDA grants priority review to efzimfotase alfa for hypophosphatasia in patients aged 2 years and older
4
Formula Feeding and the Gut Microbiome: Closing the Gap
5